Skip to content
PeptideFactSheets
DiscontinuedLimited or unclear evidence

Plain-English fact sheet

Sermorelin

Also known as Geref, sermorelin acetate

Muscle and performanceGrowth hormone research

Sermorelin was used in a former FDA-approved product that is discontinued from marketing; currently marketed compounded sermorelin products are not FDA approved.

Quick answer

Sermorelin is not currently available as an FDA-approved marketed drug product. The former Geref product was discontinued, and that history does not make current compounded versions FDA approved.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Sermorelin?

Sermorelin is a manufactured fragment of growth hormone-releasing hormone that can stimulate growth-hormone release from the pituitary gland.

A former branded product, Geref, had approved diagnostic and pediatric uses before being discontinued from marketing.

Why are people interested in it?

It is frequently promoted in anti-aging and body-composition contexts.

Those marketing claims need to be separated from the discontinued product's regulatory history and the limited evidence for today's promoted uses.

Current regulatory status

Discontinued

The FDA-approved Geref product is discontinued from marketing. Current compounded sermorelin products are not FDA-approved drug products, and discontinuation history should be checked in Drugs@FDA.

What is it approved for?

No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.

FDA approval path

Discontinued or stopped

Previously approved product discontinued

Geref, a sermorelin acetate product, was discontinued. A discontinued product is not the same as a currently marketed FDA-approved option for wellness or anti-aging use.

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

This status sits outside the standard stepwise FDA drug-approval path.

Timeline source basis

Federal Register: Geref discontinuation determinationFDA review noting Geref discontinuation

What is it being studied for?

Growth hormone secretion testing
Growth hormone deficiency in historical contexts
Growth hormone pathway effects

Investigational areas

  • Various growth-hormone-pathway outcomes outside a currently marketed FDA-approved product

Evidence snapshot

Limited or unclear evidence

Human physiology and the former product are documented, but high-quality evidence for many current wellness, anti-aging, or body-composition claims is limited or unclear.

Potential benefits being researched

  • Sermorelin can stimulate the growth-hormone pathway, which explains its historical diagnostic role.
  • A biological effect does not by itself prove meaningful anti-aging, weight, or performance benefits.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Current compounded products do not undergo FDA premarket review for safety, effectiveness, or quality.
  • Potential effects of stimulating the growth-hormone pathway can matter for glucose control, fluid retention, and other health conditions.
  • Product purity, sterility, strength, and labeling are separate concerns for unapproved products.

What we still do not know

  • Long-term safety for commonly promoted off-label wellness goals
  • Reliable benefits for anti-aging or body-composition claims
  • Consistency and quality of products outside an approved drug application

Plain-English takeaway

Sermorelin's past approval does not confer approval on products sold today. Current claims should be evaluated against current product status and human evidence.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFederal Register: Geref discontinuation determination

    FDA determination that the Geref discontinuation was not for safety or effectiveness reasons.

  2. 2
    fdaFDA review noting Geref discontinuation

    FDA clinical pharmacology review referencing the discontinued Geref product.

  3. 3
    pubmedSermorelin review

    Peer-reviewed review of sermorelin in diagnostic and therapeutic contexts.

  4. 4
    pubmedSermorelin in children with growth-hormone deficiency

    Clinical literature on historical sermorelin use in pediatric growth-hormone deficiency.